<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="74100"><DrugName>RG-7652</DrugName><DrugSynonyms><Name><Value>RG-7652</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MPSK-3169A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RO-6801831</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-PCSK9 antibody (hypercholesterolemia), Genentech</Value></Name></DrugSynonyms><CompanyOriginator id="19453">Genentech Inc</CompanyOriginator><CompaniesSecondary><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Company id="19453">Genentech Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"></TargetEntity><TargetEntity id="D006937" type="MeSH"></TargetEntity><TargetEntity id="-1478187279" type="omicsDisease"></TargetEntity><TargetEntity id="969" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="655" type="ciIndication"><TargetEntity id="10058097" type="MEDDRA"></TargetEntity><TargetEntity id="D008659" type="MeSH"></TargetEntity><TargetEntity id="-652126003" type="omicsDisease"></TargetEntity><TargetEntity id="961" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="48843" type="Action"><TargetEntity id="3596" type="Mechanism">Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) Inhibitors</TargetEntity><TargetEntity id="3673" type="Mechanism">Anti-PCSK9 (Proprotein Convertase Subtilisin/Kexin-Type 9)</TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-08850" type="ciTarget"><TargetEntity id="10271182557383" type="siTarget">Proprotein convertase subtilisin/kexin type 9</TargetEntity><TargetEntity id="-1649621866" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="174">Hypercholesterolemia</Indication><Indication id="655">Metabolic disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="48843">Proprotein convertase PC9 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2492">LDL cholesterol inhibitor</Action><Action id="71">Antihypercholesterolemic agent</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-19T09:16:44.000Z</LastModificationDate><ChangeDateLast>2018-04-20T00:00:00.000Z</ChangeDateLast><AddedDate>2011-10-14T16:50:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; was developing RG-7652 (MPSK-3169A; RO-6801831), a fully human IgG1 monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), as an LDL  cholesterol (LDL-c) lowering agent for the potential sc treatment of metabolic diseases, including hypercholesterolemia in patients with, or at high risk of, coronary heart disease [&lt;ulink linkID="1230191" linkType="Reference"&gt;1230191&lt;/ulink&gt;], [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;], [&lt;ulink linkID="1311114" linkType="Reference"&gt;1311114&lt;/ulink&gt;]. However, in July 2014, Roche listed the drug as being discontinued from development [&lt;ulink linkID="1579838" linkType="Reference"&gt;1579838&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, a phase II trial was initiated [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;], [&lt;ulink linkID="1307115" linkType="Reference"&gt;1307115&lt;/ulink&gt;]; the trial completed in July 2013 [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;]. In September 2013, phase I data were presented [&lt;ulink linkID="1472200" linkType="Reference"&gt;1472200&lt;/ulink&gt;]. In October 2013, phase II data readout was expected in 2013; at that time, Roche was seeking to outlicense the drug [&lt;ulink linkID="1488927" linkType="Reference"&gt;1488927&lt;/ulink&gt;]. However, in July 2014, Roche listed the drug as being discontinued from development [&lt;ulink linkID="1580365" linkType="Reference"&gt;1580365&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15414" linkType="Company"&gt;Chugai&lt;/ulink&gt;, &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;'s Japanese subsidiary was previously developing RG-7652, for the potential sc treatment of hypercholesterolemia. In October 2012, Chugai started a phase I trial in  Japanese patients in the US [&lt;ulink linkID="1364925" linkType="Reference"&gt;1364925&lt;/ulink&gt;], [&lt;ulink linkID="1366033" linkType="Reference"&gt;1366033&lt;/ulink&gt;]. However, in July 2014, Roche listed the drug as being discontinued from development [&lt;ulink linkID="1579838" linkType="Reference"&gt;1579838&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2012, a randomized, placebo-controlled, double-blind, phase II study (&lt;ulink linkID="88014" linkType="Protocol"&gt;NCT01609140&lt;/ulink&gt;; GC28210; EQUATOR) evaluating the safety and efficacy of RG-7652, administered by sc injection every 4 weeks for 24 weeks, in patients (n = 248) in the US, Canada, the EU, New Zealand, and South Africa with coronary heart disease or high risk of coronary heart disease [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;], [&lt;ulink linkID="1307115" linkType="Reference"&gt;1307115&lt;/ulink&gt;], [&lt;ulink linkID="1311114" linkType="Reference"&gt;1311114&lt;/ulink&gt;]. The primary outcome would be change in LDL-c concentration from baseline. At that time, the trial was estimated to complete in September 2013 [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;]. By December 2012, enrollment had completed [&lt;ulink linkID="1364388" linkType="Reference"&gt;1364388&lt;/ulink&gt;]. The trial completed in July 2013 [&lt;ulink linkID="1307109" linkType="Reference"&gt;1307109&lt;/ulink&gt;]. In September 2014,  data were presented  at the ESC 2014 Annual Congress in Barcelona, Spain. RG-7652 therapy was well tolerated  and  significantly and dose-dependently reduced LDL-c in all the arms with mean LDL-c reductions of 48 to 60% from baseline to nadir  [&lt;ulink linkID="1588954" linkType="Reference"&gt;1588954&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2012, Chugai initiated a phase I trial  in an undisclosed country outside of Japan [&lt;ulink linkID="1364925" linkType="Reference"&gt;1364925&lt;/ulink&gt;]. In January 2013, Chugai reported that the study was being conducted in Japanese patients in the US [&lt;ulink linkID="1366033" linkType="Reference"&gt;1366033&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2011, a randomized, placebo-controlled, single and multiple dose, phase I trial had been initiated in 70 subjects to evaluate the safety and tolerability of RG-7652 [&lt;ulink linkID="1230191" linkType="Reference"&gt;1230191&lt;/ulink&gt;], [&lt;ulink linkID="1259334" linkType="Reference"&gt;1259334&lt;/ulink&gt;]. In January 2013, the company planned to present phase I data later that year [&lt;ulink linkID="1364388" linkType="Reference"&gt;1364388&lt;/ulink&gt;]. In September 2013, data were presented at the 2013 ESC Congress in Amsterdam, the Netherlands. All doses tested resulted in meaningful, sustained reductions in LDL-cholesterol levels. Compared to a reduction by 6 mg/dl observed with placebo, the highest dose of 800-mg RG-7652 lowered LDL-cholesterol levels by 91 mg/dl after a single dose, whereas the 50- and 150-mg doses given weekly for 4 weeks resulted in drops by 50 and 72 mg/dl. The weekly dose of 40-mg was further tested against placebo in volunteers also receiving a statin, resulting equally in a significant advantage of 35 versus 0 mg/dl reductions of LDL-cholesterol levels. The effects of single doses of RG-7652 were long lasting and still apparent after 57 days with the doses of 300, 600 and 800 mg: long-lasting reductions were also noted on total cholesterol levels. RG-7652 was well tolerated, with no serious or severe adverse events [&lt;ulink linkID="1472200" linkType="Reference"&gt;1472200&lt;/ulink&gt;], [&lt;ulink linkID="1473505" linkType="Reference"&gt;1473505&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1580365" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-24T00:00:00.000Z</StatusDate><Source id="1579838" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-31T00:00:00.000Z</StatusDate><Source id="1364925" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="655">Metabolic disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-30T00:00:00.000Z</StatusDate><Source id="1230191" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate><Source id="1307109" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate><Source id="1307109" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate><Source id="1307109" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate><Source id="1307109" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate><Source id="1307109" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-08850"><Name>Proprotein convertase PC9</Name><SwissprotNumbers><Swissprot>A8T644</Swissprot><Swissprot>A8T650</Swissprot><Swissprot>A8T655</Swissprot><Swissprot>A8T658</Swissprot><Swissprot>A8T662</Swissprot><Swissprot>A8T666</Swissprot><Swissprot>A8T672</Swissprot><Swissprot>A8T677</Swissprot><Swissprot>A8T682</Swissprot><Swissprot>A8T688</Swissprot><Swissprot>A8T695</Swissprot><Swissprot>A8T6A1</Swissprot><Swissprot>A8T6A6</Swissprot><Swissprot>P59996</Swissprot><Swissprot>Q80W65</Swissprot><Swissprot>Q8NBP7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1266609" number="WO-2012088313" title="Anti-PCSK9 antibodies and methods of use"></PatentFamily><PatentFamily id="2598653" number="WO-2013148284" title="Antibodies that bind to a PCSK9 cleavage site and methods of use"></PatentFamily><PatentFamily id="2636711" number="WO-2013170367" title="Methods and uses for proprotein convert ase subtilisin kexin 9 (PCSK9) inhibitors"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaneka Corp" id="17639"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of British Columbia" id="20532"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>